doi: 10.3389/fimmu.2025.1547992 Received 19 December 2024 Accepted 02 May 2025 Published 26 May 2025 Volume 16 - 2025 Edited by Omowumi Adewale, Osun State University, Nigeria Reviewed by Gopal Patel, Lakshmi Narain College of Pharmacy, India Miguel Pereira-Silva, University of Texas MD Anderson Cancer Center, United States Updates Copyright 2025 Deng, Wei, Han, Li, Xu, Zhang and Zhang
Lets delve into new data to explain why this pattern exists and what it might mean for your brain health
Dont wait to start your journey towards a healthier you
External resources American Migraine Foundation - Comprehensive patient education on migraine types, treatments, and management strategies Headache journal: GLP-1 receptor agonists and migraine - Published research on GLP-1 agonists in headache disorders FDA Drug Safety Communications - Official safety information for tirzepatide and other GLP-1 agonists International Classification of Headache Disorders - Diagnostic criteria that distinguish migraine subtypes from other headache types World Health Organization: Headache Disorders - Global perspective on headache burden and classification The relationship between tirzepatide and migraines defies simple characterization
